ArticleCancer medicine2024

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.

Dejan Juric et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.